CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
about
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Gemtuzumab ozogamicin in acute myeloid leukemia.Acute myeloid leukemia: 2016 Update on risk-stratification and management.Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.Antigen-directed therapies: an effective tool in acute myeloid leukemia?CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Advances in immunotherapy for pediatric acute myeloid leukemia.CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.Targeting Leukemia Stem Cells in the Bone Marrow Niche.Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
P2860
Q33643108-832E4468-2567-498B-B74C-57EC4B8DA7EBQ37615574-ACAE3DD9-219A-40FC-8459-B672E5BEBE23Q38728718-DFAAD3B4-8415-4C0B-8BA7-46370CA5006FQ38897289-C04A12C7-C88E-4A71-AD71-6E1141D5EDD2Q39067366-B8CE2FC3-3EE7-402A-BCED-3AA42D045BE2Q39277503-36A6A88B-B5C9-49E6-A6E5-2B7FC52CA235Q40314122-DC81C5A5-87C9-463A-A170-83E9767EAB45Q40590788-C4D5BF05-4930-45FC-A1A6-4CDBF114BE14Q46426075-AD3B27F0-35AC-4FDB-85C9-CE9306023B6EQ47930962-27EA8A05-B38B-47AA-9650-B1C7E9779004Q50102761-0B3329DE-40B8-487F-9B93-21810DEBC142Q52375473-3610B63A-6CCF-40FF-BB2A-01F1BF51A1A1Q52668213-53831E1D-2193-4F29-95B2-5586C08B80A4Q55354182-4B8E0FDC-4EE5-40F1-862A-4BCA05D2F950Q57174193-69A19419-3E9A-4CD1-91DE-EA6586FFC326
P2860
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CD33 Expression and Its Associ ...... Oncology Group Trial AAML0531.
@en
type
label
CD33 Expression and Its Associ ...... Oncology Group Trial AAML0531.
@en
prefLabel
CD33 Expression and Its Associ ...... Oncology Group Trial AAML0531.
@en
P2093
P2860
P356
P1476
CD33 Expression and Its Associ ...... Oncology Group Trial AAML0531.
@en
P2093
Alan S Gamis
Betsy A Hirsch
Irwin D Bernstein
Jessica A Pollard
Michael Loken
Richard Aplenc
Robert B Gerbing
Soheil Meshinchi
Susana C Raimondi
Todd A Alonzo
P2860
P304
P356
10.1200/JCO.2015.62.6846
P407
P577
2016-01-19T00:00:00Z